Drug intelligence / Profile preview

B7-AML

Development stage: Preclinical
Lead developer: Dana-Farber Cancer Institute
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

B7-AML is a cell-based vaccine composed of irradiated acute myelogenous leukemia (AML) cells that have been genetically modified to ectopically express the B7.1 (CD80) costimulatory molecule. This vaccine is designed to induce a potent CD8+ T-cell mediated immune response against AML cells. By providing both tumor-specific antigens and the crucial B7.1 costimulatory signal, B7-AML aims to overcome the immune evasion mechanisms of leukemia and stimulate cytotoxic T lymphocytes to eliminate tumor cells. Studies have shown its potential to cure leukemia in murine models, particularly when administered early in the disease or in combination with cytoreductive chemotherapy.

Beyond the preview

Go deeper on B7-AML.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B7-AML.

Explore the full profile